DUBLIN--(BUSINESS WIRE)--The "Restless Legs Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that the restless leg syndrome therapeutics pipeline comprises of eight drug candidates in different stages of development.
Around 62% of the pipeline drug candidates are being developed as small molecule for the treatment of RLS. Hisamitsu Pharmaceutical is in a process to conduct Phase III clinical trial on its developmental drug for the treatment of RLS. In September 2017, AXIM Biotechnologies Inc. announced that it was conducting Phase I and a proof of concept clinical trial (Phase II) of MedChew RL for treatment of RLS in Israel.
Various new technologies are being used by the companies for the development of drugs to treat RLS. For instance, Hisamitsu Pharmaceutical Co., Inc. is using Hisamitsu's TDDS technology to deliver its developmental product ropinirole hydrochloride into the body through skin to maintain an adequate concentration in the blood for a long time and to avoid the first-pass effect in the liver. Alexza Pharmaceuticals Inc. is using its propriety staccato technology for the delivery of its development drug through inhalation.
The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, In April 2017, Merz Pharma GmbH & Co KgaA announced that incobotulinumtoxin demonstrated significant improvement of RLS score in the treatment of subjects with restless leg syndrome.
It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of RLS. In April 2017, Omeros Corporation announced that it owned two issued patents and one pending patent application in the U.S., and 21 issued patents and 12 pending patent applications in foreign markets directed to its discoveries linking PDE7 Program - OMS527 to movement disorders. Patent approval help in increasing opportunities for invention improvement and uniqueness.
Some of the key players developing drugs for the treatment of restless leg syndrome include Hisamitsu Pharmaceutical Co., Inc., Merz Pharma GmbH & Co KgaA, AXIM Biotechnologies Inc., and Alexza Pharmaceuticals Inc.
Key Topics Covered
1. Research Background
2. Research Methodology
3. Executive Summary
4. Pipeline Outlook
5. RLS Therapeutics Pipeline Analysis by Phase (2018)
6. Clinical Trials Review
7. Competitive Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/7fsrlm/global_restless?w=4